- Nearly 44% of men with prostate cancer drop out of active surveillance (AS) within 5 years, of whom 27.5% develop signs of disease progression.
Why this matters
- A large number of patients opting out because of signs of disease progression highlights the need for improvement in patient selection for AS.
- 10,296 men with prostate cancer on AS from Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database.
- Funding: Movember Foundation.
- 7049 men remained on AS during follow-up (>5 years follow-up, 2339;
- The cumulative incidence rate of men who remained on AS was 56.4% during 5-year follow-up.
- 43.6% of men discontinued AS or were lost to follow-up.
- 27.5% showed signs of disease progression.
- 12.8% switched to active treatment without evidence of progression.
- 1.7% of men continued watchful waiting.
- 1.7% died from other causes.
- 10-year cumulative incidence of signs of disease progression was 38.2%.
- Heterogeneity in study protocols and data collection across centers.